1. Tysnes O, Storstein A. Epidemiology of parkinson’s disease. J Neural Transmission 2017; 124:901-905.
2. Naduthota R, Bharath R, Jhunjhunwala K, Yadav R, Saini J, Christopher R, et al. Imaging biomarker correlates with oxidative stress in parkinson’s disease. Neurol India 2017; 65:263-268.
3. Ozansoy M, Başak A. The central theme of parkinson’s disease: α-synuclein. J Mol Neurobiol 2013; 47:460-465.
4. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, et al. Parkinson’s disease and the environment: Collaborative on Health and the Environment and parkinson’s Action Network (CHE PAN) conference 2007. Environ Health Perspect 2008; 117:117-121.
5. Moriguchi S, Yabuki Y, Fukunaga K. Reduced calcium/calmodulin‐dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP‐treated mice. J Neurochem 2012; 120:541-551.
6. Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of parkinson disease. Sci Rep 2013; 3:1393-1398.
7. Lofrumento D, Saponaro C, Cianciulli A, Nuccio F, Mitolo V, Nicolardi G, et al.MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011; 18:79-88.
8. Panaro M, Lofrumento D, Saponaro C, Nuccio F, Cianciulli A, Mitolo V, et al. Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of parkinson’s-like disease. Immunopharmacol Immunotoxicol 2008; 30:729-740.
9. Gainetdinov R, Fumagalli F, Jones S, Caron M. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997; 69:1322-1325.
10. Bové J, Prou D, Perier C, Przedborski S. Toxin-induced models of parkinson’s disease. NeuroRx 2005; 2:484-494.
11. Ridgel A, Peacock C, Fickes E, Kim C. Active-assisted cycling improves tremor and bradykinesia in parkinson’s disease. Arch Phys Med Rehab 2012; 93:2049-2054.
12. Petzinger G, Fisher B, McEwen S, Beeler J, Walsh J, Jakowec M. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in parkinson’s disease. Lancet Neurol 2013; 12:716-726.
13. Zigmond M, Smeyne R. Exercise: is it a neuroprotective and if so, how does it work?. Parkinsonism Relat Disord 2014; 20:123-127.
14. Aguiar A, Lopes S, Tristão F, Rial D, Oliveira G, Cunha C, et al. Exercise improves cognitive impairment and dopamine metabolism in MPTP-treated mice. Neurotox Res 2016; 29:118-125.
15. Siegel G, Chauhan N. Neurotrophic factors in Alzheimer’s and parkinson’s disease brain. Brain Res Rev 2000; 33:199-227.
16. Baquet Z, Bickford P, Jones K. Brain-derived neurotrophic factor is required for the establishment of the proper number of DA neurons in the substantia nigra pars compacta. J Neurosci 2005; 25:6251-6259.
17. Binder D, Scharfman H. Brain-derived neurotrophic factor. Growth Factors 2004; 22:123-131.
18. Cohen A, Tillerson J, Smith A, Schallert T, Zigmond M. Neuroprotective effects of prior limb use in 6‐hydroxydopamine‐treated rats: possible role of GDNF. J Neurochem 2003; 85:299-305.
19. Knaepen K, Goekint M, Heyman E, Meeusen R. Neuroplasticity—exercise-induced response of peripheral brain-derived neurotrophic factor. Sports Med 2010; 40:765-801.
20. Gomez F, Zhuang Y, Feng J, Ying Z, Fan G. Exercise impacts brain‐derived neurotrophic factor plasticity by engaging mechanisms of epigenetic regulation. Eur J Neurosci 2011; 33:383-390.
21. Razgado L, Espadas A, Reyna P, Sierra A, Anaya- V, Jimenez I, et al. The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of parkinson’s disease. PloS One 2015; 10:117391-117416.
22. Meredith G, Rademacher D. MPTP mouse models of parkinson’s disease: an update.J Parkinsons Dis 2011; 1:19-33.
23. Nam J, Leem E, Jeon M, Jeong K, Park J, Jung U, et al. Induction of GDNF and BDNF by hRheb (S16H) transduction of SNpc neurons: neuroprotective mechanisms of hRheb (S16H) in a model of parkinson’s disease. Mol Neurobiol 2015; 51:487-499.
24. Markham A, Bains R, Franklin P, Spedding M. Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: how important is BDNF?. Br J Pharmacol 2014; 171:2206-2229.
25. Yang J, Lin Y, Chuang P, Bohr V, Mattson M. BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic/apyrimidinic endonuclease 1. Neuromol Med 2014; 16:161-174.
26. Qian L, Flood P, Hong J. Neuroinflammation is a key player in parkinson’s disease and a prime target for therapy. J Neural Transm 2010; 117:971-979.
27. Tansey M, Goldberg M. Neuroinflammation in parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010; 37:510-518.
28. Fickenscher H, Hör S, Küpers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends Immunol 2002; 23:89-96.
29. Kastin A, Akerstrom V, Pan W. Interleukin-10 as a CNS therapeutic: the obstacle of the blood–brain/blood–spinal cord barrier. Mol Brain Res 2003; 114:168-171.
30. Hoffman D, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacol 1995; 120:128-133.
31. Sarkaki A , Khaksari M, Soltani Z, Shahrokhi N, Mahmoodi M. Time-and dose-dependent neuroprotective effects of sex steroid hormones on inflammatory cytokines after a traumatic brain injury. J Neurotrauma 2013; 30:47-54.
32. Fisher B, Petzinger G, Nixon K, Hogg E, Bremmer S, Meshul CK, et al. Exercise‐induced behavioral recovery and neuroplasticity in the 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned mouse basal ganglia. J Neurosci Res 2004; 77:378-390.
33. Tremblay M, Saint M, Bourhis E, Lévesque D, Rouillard C, Cicchetti F. Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging 2006; 27:862-870.
34. Miller R, James M, Sun G, Sun A. Oxidative and inflammatory pathways in parkinson’s disease. Neurochem Res 2009; 34:55-65.
35. Amor S, Puentes F, Baker D, Van P. Inflammation in neurodegenerative diseases. Immunology 2010; 129:154-169.
36. Sedelis M, Schwarting R , Huston J . Behavioral phenotyping of the MPTP mouse model of parkinson’s disease. Behav Brain Res 2001; 125:109-125.
37. Chesselet M, Richter F. Modelling of parkinson’s disease in mice. Lancet Neurol 2011; 10:1108-1118.
38. Tillerson J, Caudle W, Reveron M, Miller G. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of parkinson’s disease. Neuroscience 2003; 119:899-911.
39. Bergen JL, Toole T, Elliott R, Wallace B, Robinson K, Maitland C. Aerobic exercise intervention improves aerobic capacity and movement initiation in parkinson’s disease patients. Neurorehabil 2002; 17:161-168.
40. Allen N, Moloney N, Vliet V, Canning C. The rationale for exercise in the management of pain in parkinson’s disease. J Parkinsons Dis 2015; 5:229-239.
41. Marxreiter F, Ettle B, May V, Esmer H, Patrick C, Kragh C, et al. Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol Dis 2013; 59:38-51.
42. Tuon T, Valvassori S, Lopes J, Luciano T, Trom C, Silva L, et al. Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of parkinson’s disease. Neuroscience 2012; 227:305-312.
43. Chen J, Qin J, Su Q, Liu Z, Yang J. Treadmill rehabilitation treatment enhanced BDNF-TrkB but not NGF-TrkA signaling in a mouse intracerebral hemorrhage model. Neurosci Lett 2012; 529:28-32.
44. Sim Y, Kim S, Kim J, Shin M, Kim C. Treadmill exercise improves short-term memory by suppressing ischemia-induced apoptosis of neuronal cells in gerbils. Neurosci Lett 2004; 372:256-261.
45. Mariani E, Polidori M, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatography B 2005; 827:65-75.
46. Smeyne R, Jackson V. The MPTP model of parkinson’s disease. Mol Brain Res 2005; 134:57-66.
47. Aguiar J, Castro A, Moreira E, Glaser V, Santos A, Tasca C, et al. Short bouts of mild-intensity physical exercise improve spatial learning and memory in aging rats: involvement of hippocampal plasticity via AKT, CREB and BDNF signaling. Mech Ageing Dev 2011; 132:560-567.
48. Lin T, Chen S, Huang T, Chang C, Chuang J, Wu F, et al. Different types of exercise induce differential effects on neuronal adaptations and memory performance. Neurobiol Learn Mem 2012; 97:140-147.
49. Pietrelli A, Lopez J, Goñi R, Brusco A, Basso N. Aerobic exercise prevents age-dependent cognitive decline and reduces anxiety-related behaviors in middle-aged and old rats. Neuroscience 2012; 202:252-266.
50. Sung Y, Kim S, Hong H, Park C, Shin M, Kim C, et al. Treadmill exercise ameliorates dopaminergic neuronal loss through suppressing microglial activation in parkinson’s disease mice. Life Sci 2012; 91:1309-1316.
51. Tsou Y, Shih C, Ching C , Huang J, Jen CJ, Yu L, et al. Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal DA neurons from MPP+ toxicity. Exp Neurol 2015; 263:50-62.
52. Hong Z, Wang G, Gu J, Pan J, Bai L, Zhang S, et al. Tripchlorolide protects against MPTP‐induced neurotoxicity in C57BL/6 mice. Eur J Neurosci 2007; 26:1500-1508.
53. Qian L, Block M, Wei S, Lin C, Reece J, Pang H, et al. Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther 2006; 319:44-52.
54. Mount M , Lira A, Grimes D, Smith P, Faucher S, Slack R, et al. Involvement of interferon-γ in microglial-mediated loss of DA neurons. J Neurosci 2007; 27:3328-3337.
55. Baba Y, Kuroiwa A, Uitti R, Wszolek Z, Yamada T. Alterations of T-lymphocyte populations in parkinson disease. Parkinsonism Relat Disord 2005; 11:493-498.
56. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, et al. PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of parkinson’s disease. Eur J Neurosci 2009; 29:954-963.
57. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 2008; 441:158-162.
58. Rentzos M, Nikolaou C, Andreadou E, Paraskevas G, Rombos A, Zog M, et al. Circulating interleukin‐10 and interleukin‐12 in parkinson’s disease. Acta Neurol Scand 2009; 119:332-337.
59. Gonzalez R, Flores J, Fernandez E. Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats. Exp Neurol 2010; 226:136-147.
60. Schober A, Peterziel H, Bartheld C , Simon H, Krieglstein K, Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action. Neurobiol Dis 2007; 25:378-391.
61. Krieglstein K, Suter C, Hötten G, Pohl J, Unsicker K. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor‐β superfamily, on midbrain DA neurons. J Neurosci Res 1995; 42:724-732.
62. Ledeboer A, Brevé J, Poole S, Tilders F, Dam A. Interleukin‐10, interleukin‐4, and transforming growth factor‐β di fferentially regulate lipopolysaccharide‐induced production of pro‐inflammatory cytokines and nitric oxide in co‐cultures of rat astroglial and microglial cells. Glia 2000; 30:134-142.
63. Howells D, Porritt M, Wong J, Batchelor P, Kalnins R, Hughes A, et al. Reduced BDNF mRNA expression in the parkinson’s disease substantia nigra. Exp Neurol 2000; 166:127-135.
64. Wu S, Wang T, Yu L, Jen C, Chuang J, Wu F, et al. Running exercise protects the substantia nigra DA neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Brain Behav Immun 2011; 25:135-146.
65. Archer T, Fredriksson A. The yeast product Milmed enhances the effect of physical exercise on motor performance and dopamine neurochemistry recovery in MPTP-lesioned mice. Neurotox Res 2013; 24:393-406.
66. Parain K, Murer M , Yan Q, Faucheux B, Agid Y, Hirsch E, et al. Reduced expression of brain-derived neurotrophic factor protein in parkinson’s disease substantia nigra. Neuroreport 1999; 10:557-561.
67. Tajiri N, Yasuhara T, Shingo T, Kondo A, Yuan W, Kadota T, et al. Exercise exerts neuroprotective effects on parkinson’s disease model of rats. Brain Res 2010; 1310:200-207.
68. Lau Y, Patki G, Panja K, Le W, Ahmad S. Neuroprotective effects and mechanisms of exercise in a chronic mouse model of parkinson’s disease with moderate neurodegeneration. Eur J Neurosci 2011; 33:1264-1274.
69. Stahl K, Mylonakou M, Skare Ø, Amiry M, Torp R. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of parkinson’s disease. Brain Res 2011; 1378:105-118.
70. Baydyuk M, Nguyen M , Xu B.Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration. Exp Neurol 2011; 228:118-125.
71. Sohrabji F, Lewis D. Estrogen–BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrin 2006; 27:404-414.
72. Mattson M, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008; 60:748-766.
73. Murer M, Yan Q, Raisman R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and parkinson’s disease. Prog Neurobiol 2001; 63:71-124.
74. Rasmussen P, Brassard P, Adser H, Pedersen M , Leick L, Hart E, et al. Evidence for a release of brain‐derived neurotrophic factor from the brain during exercise. Exp Physiol 2009; 94:1062-1069.
75. Faherty C, Shepherd K, Herasimtschuk A, Smeyne RJ. Environmental enrichment in adulthood eliminates neuronal death in experimental parkinsonism. Mol Brain Res 2005; 134:170-179.
76. Ploughman M, Windle V, MacLellan C, White N, Doré J, Corbett D. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke 2009; 40:1490-1495.
77. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan W, et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1α. BMC Neurosci 2010; 11:52-61.